BR112014001409A2 - métodos e composições para vacinação contra staphylococcus aureus - Google Patents

métodos e composições para vacinação contra staphylococcus aureus

Info

Publication number
BR112014001409A2
BR112014001409A2 BR112014001409A BR112014001409A BR112014001409A2 BR 112014001409 A2 BR112014001409 A2 BR 112014001409A2 BR 112014001409 A BR112014001409 A BR 112014001409A BR 112014001409 A BR112014001409 A BR 112014001409A BR 112014001409 A2 BR112014001409 A2 BR 112014001409A2
Authority
BR
Brazil
Prior art keywords
staphylococcus aureus
against staphylococcus
compositions
methods
mammal
Prior art date
Application number
BR112014001409A
Other languages
English (en)
Portuguese (pt)
Inventor
S Ibrahim Ashraf
E Edwards John Jr
P Hennessey John Jr
R Yeaman Michael
G Filler Scott
Fu Yue
Original Assignee
Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct
Novadigm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct, Novadigm Therapeutics Inc filed Critical Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct
Publication of BR112014001409A2 publication Critical patent/BR112014001409A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014001409A 2011-07-22 2012-07-20 métodos e composições para vacinação contra staphylococcus aureus BR112014001409A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (1)

Publication Number Publication Date
BR112014001409A2 true BR112014001409A2 (pt) 2017-07-11

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001409A BR112014001409A2 (pt) 2011-07-22 2012-07-20 métodos e composições para vacinação contra staphylococcus aureus

Country Status (12)

Country Link
US (1) US10653757B2 (https=)
EP (1) EP2734229B1 (https=)
JP (1) JP2014521605A (https=)
CN (1) CN103998056B (https=)
AU (1) AU2012287513A1 (https=)
BR (1) BR112014001409A2 (https=)
CA (1) CA2842626A1 (https=)
EA (1) EA035513B1 (https=)
ES (1) ES2716800T3 (https=)
GE (1) GEP201706766B (https=)
UA (1) UA114286C2 (https=)
WO (1) WO2013015831A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
US11198724B2 (en) 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
JP6348967B2 (ja) * 2013-03-14 2018-06-27 ワン、ロンフ 制御性ｔ細胞機能を調節する方法および組成物
US10130691B2 (en) * 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP3426287A4 (en) * 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
JP7439371B2 (ja) 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025032534A2 (en) * 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP1624068A1 (en) 1993-06-01 2006-02-08 Life Technologies Inc. Genetic immunization with cationic lipids
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
DE69734601T2 (de) 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA06005639A (es) * 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
BRPI0711572A2 (pt) 2006-04-17 2011-11-16 Schering Plough Ltd organismos recombinantes atenuados de clostridium e vacinas
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
US9050281B2 (en) 2008-05-29 2015-06-09 Intervet Inc. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
US10653757B2 (en) 2020-05-19
CN103998056B (zh) 2017-09-12
EP2734229B1 (en) 2019-01-02
GEP201706766B (en) 2017-10-25
WO2013015831A1 (en) 2013-01-31
US20150273031A1 (en) 2015-10-01
AU2012287513A8 (en) 2014-06-19
CA2842626A1 (en) 2013-01-31
UA114286C2 (uk) 2017-05-25
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17
JP2014521605A (ja) 2014-08-28
EA035513B1 (ru) 2020-06-29
EA201391200A1 (ru) 2014-05-30
AU2012287513A1 (en) 2014-03-13
CN103998056A (zh) 2014-08-20
EP2734229A1 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
MX2012013261A (es) Genes ospa quimericos, proteinas, y metodos para usar los mismos.
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
BR112013026661A2 (pt) método de entrega de vacina
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BRPI0510430A (pt) composições e métodos para vacinação mucosal
WO2012170753A3 (en) Bovine vaccines and methods
BR112015001313A2 (pt) composições de vacina
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
UA114719C2 (uk) Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
BRPI0721892A2 (pt) Composição de vacina, inalador, célula, métodos para vacinar um animal contra uma infecção bacteriana, para preparar uma linhagem de célula de hibridoma, e para preparar uma vacina para um patógeno bacteriano, usos de uma composição, de soros humanos, e de um anticorpo humano, linhagem de célula de hibridoma, anticorpo, fragmento de ligação ativo, soro, processo para a produção de uma vacina, e, cultura de célula bacteriana
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.